British Journal of Ophthalmology
Công bố khoa học tiêu biểu
Sắp xếp:
High dose rate and low dose rate ruthenium brachytherapy for uveal melanoma. No association with ocular outcome
British Journal of Ophthalmology - Tập 98 Số 10 - Trang 1349-1354 - 2014
Prognosis of choroidal melanoma and the result of ruthenium brachytherapy combined with transpupillary thermotherapy in Korean patients
British Journal of Ophthalmology - Tập 97 Số 5 - Trang 653-658 - 2013
Predicting local control of choroidal melanomas following 106Ru plaque brachytherapy
British Journal of Ophthalmology - Tập 95 Số 2 - Trang 166-170 - 2011
Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm Background Episcleral brachytherapy is the most common eye-preserving treatment for medium-sized choroidal melanomas. γ-emitting iodine-125 (125 I) and β-emitting ruthenium-106 (106 Ru) are widely used. The latter is however generally reserved for thinner tumours (<6 mm). In this study, we compare ocular and patient survival in thicker tumours treated with the respective radioisotope. Methods All patients with ≥5.5 mm thick choroidal melanomas who were treated with plaque brachytherapy at a single institution between 1 November 1979 and 31 December 2015 were included (n=571). Size-controlled Cox regression HRs for postbrachytherapy enucleation, repeated brachytherapy and melanoma-related mortality were calculated, as well as Kaplan-Meier disease-specific survival and relative 10-year survival in matched subgroups. Results 317 patients were treated with 106 Ru and 254 with 125 I. The rate of repeated brachytherapy was significantly higher among patients treated with 106 Ru (8%) than with 125 I (1%, p<0.001). Size-controlled Cox regression HRs for postbrachytherapy enucleation (125 I vs 106 Ru 0.7, p=0.083) and melanoma-related mortality were not significant (125 I vs 106 Ru 1.1, p=0.63). Similarly, Kaplan-Meier disease-specific and relative 10-year survival was comparable in matched groups of 5.5–7.4 mm (relative survival 106 Ru 59%, 125 I 56%) and ≥7.5 mm thick tumours (relative survival 106 Ru 46%, 125 I 44%). Conclusions Rates of repeated brachytherapy were significantly higher among patients treated with 106 Ru versus 125 I for thick choroidal melanomas. There were, however, no significant differences in rates of enucleation or patient survival.
British Journal of Ophthalmology - Tập 104 Số 1 - Trang 26-32 - 2020
Episcleral brachytherapy of uveal melanoma: role of intraoperative echographic confirmation
British Journal of Ophthalmology - Tập 101 Số 6 - Trang 747-751 - 2017
Ruthenium-106 plaque brachytherapy for uveal melanoma
British Journal of Ophthalmology - Tập 99 Số 12 - Trang 1644-1649 - 2015
Brachytherapy and endoresection for choroidal melanoma: a cohort study
British Journal of Ophthalmology - Tập 98 Số 1 - Trang 86-91 - 2014
Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas
British Journal of Ophthalmology - Tập 93 Số 9 - Trang 1167-1171 - 2009
Posterior subcapsular cataracts and glaucoma associated with long-term oral corticosteroid therapy. In patients with rheumatoid arthritis and related conditions.
British Journal of Ophthalmology - Tập 53 Số 6 - Trang 361-372 - 1969
Corneal grafts at St John Eye Hospital, Jerusalem, January 2001-November 2002
British Journal of Ophthalmology - Tập 88 Số 7 - Trang 858-860 - 2004
Tổng số: 221
- 1
- 2
- 3
- 4
- 5
- 6
- 23